Characterization of SUMOylation of 5-HT1ARs by Sugandha, -





Submitted to the graduate degree program in Pharmacology and Toxicology and the 
Graduate Faculty of the University of Kansas in partial fulfillment of the 




________________________________         
     Dr. Nancy Muma, Ph.D., Chairperson        
  
________________________________         
Dr. Liqin Zhao, Ph.D.  
  
________________________________         










The Thesis Committee for Sugandha 








                                                                  _________________________________ 
      Dr. Nancy A. Muma, Ph.D., Chairperson  
  

















Serotonin 1A receptors (5-HT1AR) are G-protein coupled receptors involved in the control of 
mood, cognition and memory. Clinical and animal studies have demonstrated that abnormal levels 
of 5-HT1AR lead to anxiety-like and depressive-like phenotypes. Previous studies in our lab have 
shown that 5-HT1AR can undergo SUMOylation, a post-translational modification process 
analogous to ubiquitylation but involving conjugation of small ubiquitin-like modifiers (SUMOs). 
SUMOylated 5-HT1AR is located in the cell membrane and in the cytoplasm especially in the 
trans-Golgi network and endoplasmic reticulum. Differential centrifugation and receptor binding 
experiments suggest SUMOylation leads to inactivation of the 5-HT1AR, but further studies are 
needed to confirm this conclusion. Treatment with a 5-HT1AR agonist, increases the SUMOylated 
receptors which is further increased by treatment with estradiol, treatments that at pharmacological 
doses or with chronic use lead to desensitization of the 5-HT1A. Protein inhibitor of activated 
STAT xα (PiasXα) facilitates the SUMOylation of the 5-HT1AR, and treatment with estradiol and 
a 5-HT1AR agonist increases PiasXα. However, the mechanisms regulating the increase in 5-
HT1AR SUMOylation with 5-HT1AR agonist treatment alone are not known. We hypothesize 
that sentrin proteases (SENPs) catalyze the deSUMOylation of the 5-HT1AR are reduced with 
agonist treatment; however, currently, there is limited knowledge regarding which of these 
enzymes are involved in the deSUMOylation of 5-HT1AR. Thus, the goal of this study is to 
determine which SENPs are involved in the deSUMOylation of 5-HT1AR. We can then determine 
if those enzymes are altered by treatment with 5-HT1AR agonist. In the present studies, we found 
that 5-HT1AR expression is maximal at 32 hours post transfection in Neuroblastoma (N2a) cells. 
Then, we transfected N2a cells to overexpress SENPs to determine which SENPs are involved in 




deSUMOylation of the 5-HT1AR when 5-HT1AR and SUMO-1 were overexpressed in N2a cells. 
Further, we determined that there were two isoforms of SENP2 two SENP2 isoforms at 50 kDa 
and 60 kDa in the rat frontal cortex and examined whether 8-OH-DPAT, a 5-HT1AR agonist, 
treatment decreased expression of either isoform. Our results suggest that the levels of 60 kDa 
SENP2 isoform were significantly decreased with 8-OH-DPAT treatment while levels of the 50 
kDa did not change. These studies suggest that increase in SUMOylation of 5-HT1ARs due to 8-
OH-DPAT treatment may be mediated through a decrease in 60 kDa isoform of SENP2, but further 
experiments are needed to confirm this conclusion. These studies to understand the mechanism 
involved in the regulation and specifically SUMOylation of 5-HT1AR will inform the 
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CHAPTER 1: INTRODUCTION 
1.1 Serotonin 1A Receptors (5-HT1ARs) 
Serotonin 1A receptors (5-HT1ARs) are one of the most abundant and widely studied 
receptor subtype. It is present in brain areas that are involved in controlling mood, emotion and 
memory [1]. 5-HT1ARs belong to the family of inhibitory G-protein coupled receptors (GPCRs) 
and function by coupling to Gi/Go family of proteins and control numerous intracellular signaling 
cascades [2, 3]. In a mammalian brain, 5-HT1AR exist as two populations-autoreceptors that 
mediate negative feedback or as heteroreceptors that mediate post-synaptic inhibitory responses to 
serotonin. Autoreceptors are present on the soma and dendrites in the raphe nuclei [4]. 
Autoreceptor activation reduces neuronal excitability by hyperpolarizing the membrane, therefore 
suppressing neuronal transmission [5]. Post-synaptic heteroreceptors are expressed in limbic and 
cortical regions of the brain such as hippocampus, amygdala, hypothalamus, frontal cortex, which 
modulates mood, learning and memory [6, 7]. Therefore, 5-HT1ARs expressed in these brain 
regions are important targets in various psychological disorders.  
Moreover, impairment in the function of 5-HT1ARs may lead to anxiety, depression and 
other mood related disorders [8-10]. Several postmortem studies in suicide and depressed patients 
suggest decreased binding of 5-HT1ARs as compared to healthy individuals [11]. Some 
postmortem studies have also shown increased 5-HT1AR levels in prefrontal cortex in 
schizophrenia [12]. Positron emission tomography (PET) studies have shown a reduction in both 
pre and post- synaptic 5-HT1ARs in depressed patients [13]. Also, reduced 5-HT1AR levels were 
found in amygdala, cortex and raphe nuclei in patients with social anxiety disorders and panic 




knockout of the 5-HT1AR led to the development of an anxiety-like phenotype in mice while early 
overexpression of the receptor reduced the phenotype [16]. 5-HT1AR knockout mice display 
decreased exploratory activity and increased fear of open fields [17]. Specific deletion of 5-HT1A 
heteroreceptors in the dentate gyrus eliminated the effects of SSRIs in several behavioral tests [18]. 
Together these studies demonstrate that 5-HT1ARs are important targets in anxiety and depression.  
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, and citalopram are the 
most commonly prescribed anti-depressant drugs [19]. SSRIs prevent the reuptake of serotonin by 
blocking the serotonin transporter (SERT) thereby, increasing the levels of serotonin in the 
synapse. However, 3-4 weeks of treatment with SSRIs is required to see the clinical effects of 
these drugs. Initial rise in the levels of serotonin in the synapse activates the 5-HT1A autoreceptors 
and they exert a negative feedback inhibition, resulting in decreased serotonin release[20]. 
Sustained use of the anti-depressants leads to the desensitization of the somatodendritic 5-HT1A 
autoreceptor [21]. This results in an increased serotonergic neuron firing rate and serotonin 
neurotransmission [22]. The specific blockade of 5-HT1A autoreceptors by pindolol, an anti-
hypertensive drug which is also a partial antagonist of 5-HT1ARs, escalates the clinical effects of 
SSRIs [23, 24]. Several animal studies suggest that the desensitization of the presynaptic 5-HT1A 
autoreceptors accelerates the onset of action of many anti-depressant drugs [25]. Studies show that 
mice with higher 5-HT1A autoreceptor levels were not able to respond to acute stress, and showed 
no behavioral response to anti-depressants [15]. Several studies suggest that preferential activation 
of the post-synaptic 5-HT1A heteroreceptors leads to anti-depressant like effect [26]. Overall, 
these studies suggest that activation of post-synaptic 5-HT1ARs or blockade/desensitization of 




Since, 5-HT1ARs are involved in these affective disorders, it is important to understand 
how they are regulated. Several studies have demonstrated that 5-HT1ARs undergo various post 
translational modifications (PTMs).  
1.2 Post Translational Modifications (PTMs) 
Post translational modification is a process which involves the attachment of chemical 
moieties such as sugars, lipids or polypeptides to a protein after its translation. PTMs of proteins 
may affect the enzymatic activity, localization and may alter its interactions with other proteins. 
PTMs may also alter the signaling cascades downstream of their target proteins [28, 29]. There are 
many post translational modifications such as ubiquitination, palmitoylation, phosphorylation, 
acetylation, glycosylation etc. 
1.2.1 PTMs of 5-HT1ARs:  
5-HT1ARs are known to undergo the following PTMs- palmitoylation [30], 
phosphorylation [31] and SUMOylation [32]. Studies suggest that palmitoylation is an irreversible 
modification. The 5-HT1AR is modified by palmitic acid, where the fatty acid gets attached to the 
cysteine residues 417 and 420 of the 5-HT1AR. Palmitoylation may either be required for the 
interaction of the 5-HT1AR with G-proteins or it could help in the trafficking of the receptor to 
the detergent resistant membrane (DRM) of the plasma membrane. Phosphorylation of 5-HT1ARs 
mediated by protein kinase C is involved in the desensitization of the receptor [33]. Our lab has 
recently shown that 5-HT1ARs undergo SUMOylation. 
1.2.2 SUMOylation: 
SUMOylation is a reversible and transient process where a member of the Small Ubiquitin-




protein. This process is governed by an enzymatic pathway which is very similar to the 
ubiquitination pathway[34]. The SUMO family is highly conserved in all eukaryotes. SUMO 
proteins belong to the family of Ubiquitin-like proteins (Ulps). There are four SUMO isoforms 
present in mammals: SUMO1 to SUMO4[35, 36]. SUMO1 is 101 amino acid long and 
approximately 11.5 kDa [37, 38]. It is 18% similar to ubiquitin. SUMO2 and SUMO3 are nearly 
identical to each other and are often referred to as SUMO2/3. They differ only by 3 amino acids 
residues at the N-terminal. SUMO1 and SUMO2/3 share around 47% homology.  SUMO4 is the 
least characterized of all, and no modified substrate has been reported [39]. Some studies suggest 
that SUMO4 may be unable to SUMOylate any substrate protein because of a proline residue that 
is present in its sequence which hinders its maturation to an active SUMO form [40].  
SUMOylation has a variety of effects on the cells. It is involved in changing the interaction 
with DNA, RNA or other proteins [41]. Several studies suggest that SUMOylation changes the 
conformations and the enzymatic activities of its target proteins.  SUMOylation also modulates 
other protein modifications [42]. Various studies have demonstrated that deleting or knocking 
down the SUMO genes or any components involved in the SUMO pathway is fatal for mammalian 
cells [43]. Many studies suggest that SUMOylation dysfunction may lead to various 
neuropathological problems [34]. Thus, studying the SUMO pathway and the enzymes involved 
in SUMOylation is important to understand the role of SUMOylation in the affective disorders. 
1.2.3 The SUMO Pathway: 
SUMOylation is a dynamic pathway that leads to the formation of an isopeptide bond 
between the carboxy terminal of the SUMO protein to the ɛ-amino group of a substrate [44]. It 
usually occurs on a consensus motif of the substrate protein (Ψ-K-X- [D/E]), where Ψ is any large 




aspartate or glutamate) [29].  The SUMO isoforms are translated as inactive precursor proteins 
which are cleaved by the family of enzymes called sentrin proteases [34]. These enzymes expose 
the diglycine site on the C-terminal of the SUMO protein which is required for conjugation. SUMO 
proteins are then adenylated by the ATP-dependent formation of a thioester bond with the active 
site of the E1 enzyme (heterodimer of SUMO activating enzyme subunit 1 and subunit 2, SAE1 
and SAE2). The activated SUMO is transferred to the substrate protein with the help of E2 
conjugating enzyme called Ubiquitin conjugating enzyme 9 (Ubc9) [45, 46]. Ubc9 often works in 
conjunction with E3 ligases to catalyze the transfer of SUMO to the target protein. Since, 
SUMOylation is a reversible process, the SUMO proteins are deconjugated from the substrate 
protein by sentrin proteases.  
1.3 Sentrin Proteases:  
Despite being a covalent interaction, SUMOylation can be easily reversed by isopeptidase 
activity of deSUMOylation enzymes. These deSUMOylation enzymes are referred to as SUMO 
specific proteases or SUMO isopeptidases. The known SUMO-specific isopeptidases and 
proteases are cysteine proteases which are classified into three families: the Ulp/SENP (ubiquitin-
like protease/ sentrin-specific protease) family, the Desi (deSUMOylating isopeptidase) family 
and USPL1 (ubiquitin-specific peptidase-like protein 1).  
Ulp/SENP proteins belong to the C48 family subgroup of the Cysteine E (CE) superfamily 
of thiol proteases. Ulp1 was the first protease to be discovered in the yeast, Saccharomyces 
cerevisiae, while Ulp2 (Smt3 specific proteases) was the second [47]. Initially in humans, there 
were seven proteases classified into Ulp family members which were known as SENPs [48]. Later 
on it was found that SENP8 does not act on SUMO paralogs, instead acts on Nedd8, a ubiquitin-




mechanistic relatives, deubiquinating enzymes (DUBs). Finally, there are six SENPs that are 
involved in deSUMOylation, SENP 1, SENP2, SENP3, SENP5, SENP6 and SENP7. Sequence 
analyses studies demonstrate that SENP1, SENP2, SENP3 and SENP5 are evolutionary related to 
Ulp1 branch whereas SENP6 and SENP7 are more similar to Ulp2 branch. These studies further 
reveal the pairwise similarities between SENP1 and SENP2, SENP3 and SENP5, SENP6 and 
SENP7. Ulp/SENPs are cysteine proteases and possess a conserved C-terminal domain with His-
Asp-Cys catalytic triad and a distinct N-terminal region. The non-conserved N-terminal domain 
of the Ulp/SENPs determines the subcellular localization and substrate specificity of these 
proteases. These enzymes have characteristic subcellular locations which also determines their 
activity towards specific substrates. Most SENPs also contain several SUMO interacting motif 
(SIMs) modules in their N-terminal domains, which may contribute to the selection of substrates 
or facilitate the targeting of specific SENPs to poly-SUMO chains. Ulp1 is found at the 
nucleoplasmic face of the nuclear pore complex (NPC), and Ulp2 is found in the nucleoplasm. 
SENP1 contains both N-terminal localization signals (NLS) and nuclear export signals (NES), but 
is primarily present in the nucleus [51-53]. SENP2 being closely related to SENP1, is also found 
in nuclear membrane along with NPC [54, 55]. SENP3 and 5 reside in nucleolus and cytoplasm 
[56] while SENP6 and 7 are present in nucleoplasm.  
The deSUMOylating isopeptidases (Desi) family consists of two enzymes, Desi 1 and Desi 
2. They belong to C97 family of cysteine proteases [57]. These proteases are found in plants and 
metazoan but are absent in lower eukaryotes such as yeast. Studies have shown that Desi 1 forms 
a homodimer, in which the groove between the two subunits forms the active site. This region 
consists of two conserved cysteine and histidine residues that form a catalytic dyad [57, 58]. Desi 




USPL1 is the only known mammalian SUMO-specific protease which belongs to the C98 
family [59]. USPL1 is found in invertebrates and metazoan vertebrates. Unlike Ulp/SENPs, 
USPL1 shows sequence homology to ubiquitin-deconjugating enzyme USP1. USPL1 contains a 
catalytic triad composed of Cys-His-Asp residues [59, 60]. USPL1 is primarily found in nucleus. 
In humans, SENPs act as deconjugating as well as maturation and processing enzymes. 
SENPs help in the maturation of SUMO proteins by exposing the C-terminal diglycine moiety on 
inactive SUMO proteins and help initiate the SUMOylation process. Different SENPs have 
different activities in either deconjugation or processing depending on the substrate specificity of 
the SENPs. The substrate specificity of SENPs is determined by the amino acids that are found on 
the C-terminal to the di-glycine motif. For example, SENP1 displays little specificity for 
deconjugation of SUMO2 and SUMO3 while it is essential for the deconjugation of SUMO1-
modified proteins[61, 62]. SENP2 catalyzes deconjugation better than processing and 
deconjugates Ran GTPase Activating Protein 1 SUMO-1 (RanGAP1-SUMO-1), RanGAP1-
SUMO2 and Ran-GAP1-SUMO3 with similar efficiency. SENP2 possesses different substrate 
specificities during processing, for example, it processes SUMO2 more efficiently than SUMO1 
and SUMO3 [62]. SENP3 and SENP5 show both processing and deconjugating activity for 
SUMO2 and SUMO3 but possess neither for SUMO1. SENP6 and SENP7 have eminent 
deconjugating activity for poly SUMO2/3 chains while exert very weak processing or 
deconjugating activity on monomeric SUMO modified substrates. 
SENP enzymes play an important role in maintaining normal cellular functions by keeping 
a balance between SUMOylated and un-SUMOylated proteins. These enzymes are required for 
proper cell cycle progression. Several studies have shown that knockout of SENP1 or SENP2 in 




64]. Studies have depicted the role of SENP enzymes in the development and progression of cancer 
especially in prostate cancer [65, 66]. Many studies have demonstrated that SENP1 activates 
oncogenic signaling pathways such as c-Jun and androgen-receptor mediated transcription.  
In this study, we have chosen to use SENP1, SENP2 and SENP6 based on their substrate 
specificities. As described before, these 3 SENPs show substrate specificity towards SUMO1 
while SENP3 and SENP5 do not possess any activity for SUMO1.  
1.4 SUMOylation of 5-HT1ARs: 
My thesis project focuses on the SUMOylation of 5-HT1ARs. Previous studies in our lab 
have shown that 5-HT1ARs are SUMOylated by SUMO1 in the rat brain tissue. SUMOylated 5-
HT1ARs were detected in the membrane fractions of cortex, amygdala, hippocampus, 
hypothalamus, dorsal raphe and midbrain but not in the cytosolic fractions, as demonstrated by 
immunoprecipitation and immunoblotting [32].  Using differential centrifugation, receptor binding 
assays and western blotting, Li et al [32] observed that 5-HT1ARs that were bound to (+)8-
hydroxy-2-dipropylaminotetralin (8-OH-DPAT) did not overlap with SUMOylated 5-HT1ARs 
suggesting that SUMOylated 5-HT1ARs have a low affinity for 8-OH-DPAT. Also, it was 
observed that SUMOylated 5-HT1ARs did not exist in the same fractions as Gαz proteins which 
couple to the receptors. These results suggest that SUMOylation of 5-HT1ARs inactivates the 5-
HT1ARs, but more studies are needed to verify this interpretation.  
To determine the location of the SUMOylated 5-HT1ARs, Li et al [32] performed a cold 
tritonX-100 treatment followed by sucrose gradient centrifugation in order to isolate the detergent 
resistant microdomain (DRM). They found that majority of the SUMOylated receptors were 




the subcellular distribution of the SUMOylated 5-HT1ARs, Li et al conducted a discontinuous 
gradient centrifugation using 7.5-30% iodixanol. It was observed that the SUMOylated receptor 
predominantly co-localized with TGN-38, a marker for trans golgi network (TGN) and 
calreticulin, a marker for the endoplasmic reticulum (ER). A small fraction of the SUMOylated 
receptors were found in the plasma membrane, determined by the Na+/K+ ATPase. Imaging-based 
approaches were used to confirm the subcellular location of SUMOylated 5-HT1AR. Robust 
labelling and co-localization of SUMO1 and 5-HT1ARs antibodies were demonstrated in the 
plasma membrane of SH-SY5Y cells. SUMO1 and 5-HT1ARs antibodies were also found to 
FRET in the peri-nuclear region as well as the plasma membrane. This further supports the 
previous data that SUMOylated receptors are located in the TGN and ER of the cell.  
Acceptor photobleach Förster resonance energy transfer (FRET) was performed to 
determine the primary site of SUMOylation on 5-HT1AR. SUMO prediction programs were used 
to predict lysine residues on 5-HT1ARs that could get SUMOylated. Mutant 5-HT1ARs were 
constructed wherein the identified lysine (K) residues were mutated to arginine (R). Either the 
wild-type 5-HT1AR or the mutant 5-HT1AR were transfected in the SHSY5Y cells and it was 
seen that there was a small but significant increase in the FRET distance with K324R, K232.235R 
and K232.235.324R mutants as compared to the wild-type 5-HT1A receptor suggesting that lysine 
232, 235 and 324 of the amino acid sequence of the 5-HT1AR could be SUMOylated. However, 
further studies are needed to confirm the exact site of SUMOylation [77]. Next, we will be using 
mass spectrometry analysis to identify the primary site of SUMOylation on 5-HT1ARs. 
Estrogens are involved in regulation of emotional states. Administration of estrogens such 
as estradiol were shown to accelerate the desensitization of the 5-HT1ARs in the paraventricular 




mediated by estrogens [14, 15]. Previous studies in our lab have shown that treatment with 
estradiol in conjunction with a SSRI, fluoxetine accelerates fluoxetine-induced desensitization of 
5-HT1ARs in the PVN [16]. However, further studies are needed to confirm the mechanism 
involved in estradiol mediated desensitization of 5-HT1ARs. 
Previous studies in our lab have shown that 5-HT1ARs are SUMOylated and treatment 
with 8-OH-DPAT, an agonist of 5-HT1AR, increased the SUMOylated receptors and treatment 
with 17β-estradiol-3-benzoate (EB) for 2 days further increased the SUMOylation of 5-HT1ARs. 
Hence, we hypothesize that SUMOylation could be involved in the desensitization of the 5-
HT1ARs mediated by estradiol. Therefore, it is important to understand the role of SUMOylation 
in 5-HT1AR functioning and the mechanisms underlying the SUMOylation of 5-HT1ARs.  
To understand the mechanism of SUMOylation of 5-HT1ARs, one of the previous students 
in our lab performed immunoprecipitation and immunoblotting studies to identify which PIAS 
proteins facilitate the SUMOylation of the 5-HT1ARs. Different PIAS constructs were transfected 
in N2a cells and it was observed that PiasXα significantly increased the SUMOylation of 5-
HT1ARs. Also, PiasXα expression significantly increased in the membrane fraction of the rat PVN 
when treated with EB and 8-OH-DPAT as compared to rats treated with 8-OH-DPAT alone. 
1.5 Statement of Purpose: 
The purpose of this study is to determine the enzymes that regulate deSUMOylation of 5-
HT1ARs and determine if treatment with a 5-HT1AR agonist decreases the expression of that 
SENP. Previous studies demonstrated that treatment with a 5-HT1AR agonist increases the 




enzyme PiasXα increases the SUMOylation of 5-HT1ARs however treatment with the 5-HT1AR 
agonist 8-OH-DPAT did not result in an increase in PiasXα or any other Pias protein.   
The second goal of this study focuses on finding the primary site of SUMOylation of 5-
HT1ARs. Identifying the SUMO site would help us better understand the 5-HT1AR structure and 
function. Mutating the site where 5-HT1AR gets SUMOylated will help us understand how the 5-
HT1AR function is modulated in the absence of SUMOylation. 
Overall, these goals would help us gain more insight into the regulation of 5-HT1AR 




CHAPTER 2: MATERIALS AND METHODS 
2.1. Plasmid constructs: 
The plasmid constructs that were used in the experiments are listed in the table below. The 




Plasmid Vector Tag Source 
pcDNA4 HisMax C- 5-
HT1A Receptor 
pcDNA4 HisMax C His, 
   Xpress 
- 
 pEGFP-N1 pEGFP-N1  EGFP - 
 pcDNA3+SUMO1 pcDNA3  His - 
pEFIFRES-P-6His SUMO1 
 
 pSCAI80  His 
 
A gift from Dr. Ronald 
T Hay (University of 







Flag-SENP1 pFLAG-CMV Flag Plasmid# 17357, 
Addgene  
Flag-SENP2 pFLAG-CMV Flag Plasmid# 18047, 
Addgene 





2.2 Cell culture and transfections: 
Mouse Neuroblastoma cells (N2a cells) were cultured in 50% Dulbecco’s modified eagle 
medium (1X DMEM, high glucose, pyruvate, Thermo Fisher, USA)  and 50% Opti-MEM (Thermo 
Fisher, USA) along with 10% Foetal Bovine Serum (Atlanta Biologicals, USA) and 1% Penicillin-
Streptomycin (Sigma Aldrich, USA). For transfections, cells were transfected with the mammalian 
expression vectors (Table 1) in the 10 cm plates after 20-24 hours of plating with Lipofectamine 
3000 (Thermo Fisher, USA). Media was changed after 4 hours of transfection. After 32 hours of 
transfection, cells were harvested. 
 
2.3 Harvesting: 
Harvesting was done either 32 or 48 hours post transfection. For harvesting, cells were first 
washed with 1x Phosphate buffered saline (1xPBS) and then with hypotonic buffer (0.25M sucrose 
50 mM Tris, pH 7.5, 5mM EDTA, 100 mM NaCl). Cells were harvested with hypotonic buffer 
containing 20mM N-ethylmaleimide (NEM), 1/100 dilution of phosphatase inhibitors (Sigma 
Aldrich, USA) and protease inhibitors (Sigma Aldrich, USA) were added fresh) and centrifuged 
for 1 hour. Then the supernatant was removed as the cytosolic fraction and the pellet was 
resuspended in the solubilization buffer (20 mM Tris, pH 8, 1 mM EDTA, 100 mM NaCl. 1% 
sodium cholate, 20mM NEM, 1/100 dilution of phosphatase inhibitors and protease inhibitors were 
added fresh). After sonication, the vials were shaken horizontally at 4oC for at least 1 hour. After 
this, vials were centrifuged at 25000xg for 1 hour. The supernatant was removed as the membrane 




BCA Protein Assay, Cat#23209, Albumin Standard, Thermo Fisher, USA) was performed to 
determine the protein concentrations. 
 
2.4 Tissue Preparation: 
Ovariectomized female rats were injected with either saline or 8-OH-DPAT (200 µg/kg) 
subcutaneously and then decapitated 5 minutes later. Brains were removed, frontal cortex was 
dissected, frozen on dry ice and stored at -80°C until use.  
Tissue was homogenized using 100ul homogenization buffer (50 mM Tris, pH 7.4,10 mM 
EGTA, 100 mM NaCl, 0.5% Triton X-100. 20mM NEM, 1/100 dilution of phosphatase inhibitors 
and protease inhibitors were added fresh) using motorized homogenizer (Powergene 1000 with 
5mm probe) at speed 5, 4°C for 3 minutes or until all of the tissue was homogenized. The procedure 
for isolation of the membrane fraction of frontal cortex was the same as that for cell lysates.   
 
2.5 Immunoprecipitation (IP): 
After harvesting, immunoprecipitation was done using 450 µg of protein from the 
membrane fractions of the cell lysates. The samples were added to pre-washed 50 µl of protein G 
Dynabeads (Cat #1003D, Invitrogen, Thermo Fisher, USA) and volume was made up to 500 µl 
with ice-cold IP buffer (50 mM Tris, pH 7.4, 10 mM EGTA, 100 mM NaCl, 0.5% Triton X-100. 
20 mM NEM, 1X protease inhibitor cocktail, 1X phosphatase inhibitor cocktail I and II were added 
fresh) and then were rotated for 1 hour at 4oC. Then the beads were removed, and either the 10 µg 




samples and shaken at 4oC overnight. After 12-16 hours of incubation, 75µl of pre-washed beads 
were added to the samples and shaken for 2 hours. Then the beads were washed three times and 
the proteins were eluted using 2x sample buffer with 2-mercaptoehanol by incubating at 95oC for 
5 minutes. The protein samples were then stored at -80oC or resolved on a gel. 
 
2.6 His-Tag Purification: 
For his-tag purification, 300 µg protein from the membrane fractions of the cell lysates was 
used. A polyHis Pull-down assay kit (Cat#21277, Invitrogen, Thermo Fisher, USA) was used. 
PolyHis proteins were pulled down using cobalt affinity beads from the kit. Sample was added to 
50 µl of pre-washed beads and incubated overnight at 4oC. After 12-16 hours of incubation, beads 
were washed several times with a lysis buffer from the kit. The his-tagged samples were eluted 
using 100 mM imidazole solution. Then the eluted sample was filtered through a 30-kDa-cutoff 
filter device (Cat# VN01H22, Sartorius, USA) to eliminate imidazole before it was run on an SDS-
PAGE gel. 
 
2.7 Western blotting (WB): 
Protein samples were resolved on a 10% polyacrylamide SDS gel at 150 V for 60-70 
minutes and then transferred to a Polyvinylidene difluoride (PVDF) membrane at 100 V for 2 
hours. Then the membrane was incubated in 5% non-fat dry milk in 1x Tris buffered saline and 
Tween 20(1xTBST) for 1 hour at room temperature. After this, the membrane was incubated in 




washed and incubated with the appropriate secondary antibodies listed below (Table 2), for 1 hour 
at room temperature. 
Immunodetection was performed using an ECL kit (GE Healthcare, USA and BioRad, 
USA) and ImageLab 3.0 software (BioRad, Hercules, CA). The protein levels were normalized to 
β-actin bands.  
Table 2. Antibodies used for immunoblotting and immunoprecipitation: 
 
Antibodies  Dilution (WB)/ 
Amount (IP) 
Source 
Rabbit anti- 5-HT1AR  1:1000 Cat# PAS-28090, Invitrogen, 
Thermo Fisher, USA 
Mouse anti- 6xHis  1:500 Cat#Y1011, UBPBio, USA 
Rat anti-Flag 1:500 Cat# 200474-21, Agilent, USA 
Mouse anti-Flag   3 µg Cat# MA1-91878, Invitrogen, 
Thermo Fisher, USA 
Mouse anti-SUMO-1 (D-
11) 
10 µg Cat# sc-5308, Santa Cruz 
Biotechnologies, USA 
Rabbit anti-SENP2  1:500 Cat# PA5-86255, Invitrogen, 
Thermo Fisher, USA 
Mouse IgG isotype control 10 µg Cat# 31903, Invitrogen, 
Thermo Fisher, USA 
Goat anti-Mouse IgG 1:20000 Cat# 119380, Jackson 
ImmunoResearch, USA 
Goat anti-Rabbit IgG 1:20000 Cat# 120745, Jackson 
ImmunoResearch, USA 
Goat anti-Rat IgG 1:20000 Cat#112-035-003, Jackson 
ImmunoResearch, USA 





2.8 Statistical Analysis 
All data were analyzed by one-way ANOVA or unpaired t-tests using a GraphPad Prism 
software (Version 6.02). Data analyzed by one-way ANOVA were followed by post hoc tests such 
as Dunnett’s multiple comparison test (comparison with a control).  All data are presented as mean 





CHAPTER 3: RESULTS 
3.1 Overexpression of 5-HT1A receptors 
To determine the optimal time of 5-HT1A receptor overexpression, a time-course 
experiment with the N2a cells was performed. N2a cells were transfected with the flag tagged 5-
HT1AR (DYK-5-HT1AR) and harvested 32, 40 and 48 hours after transfection. Immunoblotting 
was performed using the anti-flag antibody. Our results show that the expression of the 5-HT1A 
receptor is maximum 32 hours after transfection (Figure 1). The first time-point we tested was 32 
hours although there could be higher expression of the 5-HT1AR before 32 hours. 
 
3.2 Identification of SUMOylated 5-HT1A receptor 
To determine if there is any difference in the size of SUMOylated 5-HT1A receptor of 
different species, rat and human constructs of 5-HT1A receptor were transfected in N2a cells. Rat 
and mouse cortex tissue were also examined. As N2a cells also express 5-HT1A receptor 
endogenously, a non-transfected control was also included in this experiment. Membrane fraction 
of the cell lysates and tissue homogenates was immunoprecipitated using mouse monoclonal 
SUMO1 antibody and examined on immunoblots with rabbit polyclonal 5-HT1A receptor 
antibody. We observed the SUMOylated 5-HT1A receptor band around 50 kDa in all the samples 
demonstrating that there is no difference in the size of the SUMOylated receptor among different 
species and the polyclonal antibody was able to detect SUMO1-5-HT1AR from all species 




3.3 Effect of different SENPs on the SUMOylation of 5-HT1A receptors 
To determine which SENP enzyme is involved in the deSUMOylation of 5-HT1A 
receptors, the N2a cells were transfected with flag tagged SENP1, SENP2 and SENP6. The 
expression of the SENP enzymes in the membrane fractions were detected using an anti-flag 
antibody (Figure 3A). Membrane fraction of the cell lysates was immunoprecipitated using mouse 
monoclonal SUMO1 antibody and immunoblotted with rabbit polyclonal 5-HT1A receptor 
antibody to detect the SUMOylated 5-HT1A receptor (Figure 3B). The experiment was repeated 
three times. One-way ANOVA followed by Dunnet’s multiple comparison post hoc tests shows 
no significant difference in the amount of SUMOylated 5-HT1AR in the presence of any of the 
SENPs (F(3.8)=1.511, p=0.28) (Figure 3C). 
 
3.4 Effect of different SENPs on the SUMOylation of 5-HT1A receptors with 
overexpression of 5-HT1ARs and SUMO1 
To determine which SENP enzyme is involved in the SUMOylation of 5-HT1ARs, we used 
another approach, in which we overexpressed DYK-5-HT1AR and SUMO1 along with SENP1, 
SENP2 and SENP6. Cells were harvested 32 hours after transfection. Membrane fractions of the 
cell lysates were immunoprecipitated with mouse anti-SUMO1 antibody and immunoblotted with 
either rat anti-flag antibody (Figure 4A) or rabbit anti-5-HT1AR antibody (Figure 4C). Each 
experiment was repeated three times and four times respectively. The flag antibody labeled the 
SUMOylated 5-HT1AR at 42 kDa, which is lower than the previously observed molecular weight 
of SUMOylated 5-HT1ARs i.e. at 55 kDa. However, the 5-HT1AR antibody labeled the 




of SUMOylated 5-HT1AR as compared to the control when one-way ANOVA was performed 
followed by Dunnett’s multiple comparison test both in case of anti-flag antibody (F(3,8)= 4.907, p 
< 0.05; Figure 4B) and anti-5-HT1AR antibody (F(3,12) = 4.907, p<0.0001; Figure 4D). 
 
3.5 Effect of 8-OH-DPAT treatment on the expression of SENP2 in rat frontal 
cortex 
Since, SENP2 catalyzes the deSUMOylation of 5-HT1ARs, we hypothesize that SENP2 
decreases with 8-OH-DPAT treatment resulting in increase in the SUMOylation of 5-HT1ARs. To 
determine if the SENP2 expression decreases with 8-OH-DPAT treatment, SENP2 protein levels 
were examined on immunoblots. Membrane fraction of the frontal cortex samples from rats treated 
with 8-OH-DPAT or saline was examined on immunoblots with an anti-SENP2 antibody (Figure 
5A). We observed two isoforms of SENP2 at 50 kDa and 60 kDa molecular weight. Unpaired t-
test results show that there is no significance difference in the expression of SENP2 with 8-OH-
DPAT treatment and the control for the lower bands i.e. 50 kDa molecular weight isoform of 
SENP2 (Figure 5B). However, unpaired t-test results for the upper bands i.e. 60 kDa molecular 
weight isoform show a significant decrease in the expression of SENP2 with 8-OH-DPAT 
treatment as compared to the saline treated group (Figure 5C). 
 
3.6 Purification of 5-HT1ARs and SUMOylated 5-HT1ARs 
To identify the primary site of SUMOylation on 5-HT1ARs, mass spectrometry studies 




SUMOylated 5-HT1AR is required. The following procedure is used to purify the 5-HT1AR and 
SUMOylated 5-HT1AR. N2a cells are either transfected with 5-HT1AR and/or 6His-
SUMO1(T95K). Cells were harvested 32 hours after transfection. Membrane fractions of the cell 
lysates were immunoprecipitated using anti-flag antibody in order to purify the 5-HT1AR. The 
samples were run on a 10% SDS-PAGE gel and the gel was stained with Coomassie blue stain 
(Figure 6A). Next, his-tagged pull down was performed on the membrane fractions to purify the 
















Figure 1. Optimization of transfection time for overexpression of 5-HT1ARs.  
N2a cells were transfected with pcDNA3.1+/C-(K)DYK 5-HT1AR plasmid and cells were 
harvested 32, 40 and 48 hours after transfection. 20, 25 and 30 μg of proteins from membrane 
fractions of the lysates were examined on immunoblots with an anti-flag antibody. 5-HT1AR 
expression was maximum when harvested 32 hours after transfection. The bands at 37 kDa are 


















Figure 2. Comparison of the SUMOylated 5-HT1ARs across different species. 
Membrane fractions of either N2a cell lysates or tissue homogenates were immunoprecipitated 
with mouse anti-SUMO1 antibody and examined on immunoblots with rabbit anti-5-HT1AR 
antibody. Blot shows that the molecular weight of SUMOylated 5-HT1AR is similar in human, rat 
and mouse tissues and transfected cells. NT: Non- transfected, Rat R: Rat 5-HT1AR construct, 
Human R: Human 5-HT1AR construct, Rat CT: rat cortex tissue, Mouse CT: mouse cortex tissue, 






















Figure 3.  Effect of SENPs on SUMOylated 5-HT1ARs. 
 N2a cells were transfected with flag-tagged SENP plasmid constructs and were harvested 48 hours 
after transfection. (A) Western blot showing the expression of SENPs in the membrane fractions 
of N2a cell lysates using an anti-flag antibody. (B) Membrane fractions were immunoprecipitated 
using an anti-SUMO1 antibody and immunoblotted with 5-HT1AR antibody to determine the 
effect of SENPs on the SUMOylated 5-HT1ARs (C) Graph showing the quantification of the 
SUMOylated 5-HT1AR. Data are shown as mean ± SEM (n=3). SENPs did not significantly alter 





























































Figure 4.  Effect of SENPs on SUMOylated 5-HT1ARs with overexpression of 
5-HT1ARs and SUMO1.  
N2a cells were transfected with DYK-5-HT1AR and WT-SUMO1 plasmids along with either GFP 
(Control) or different flag-tagged SENPs. NT indicates non-transfected lysates. Cells were 










































































































immunoprecipitated using an anti-SUMO1 antibody and immunoblotted using either (A) an anti-
flag antibody or (C) an anti-5-HT1AR antibody. (B) Graph showing the quantification of 
SUMOylated 5-HT1AR on the blots labelled with an anti-flag antibody. Data are shown as mean 
±SEM (n=3). One-way ANOVA shows a significant effect of SENP expression on SUMOylated 
5-HT1AR expression levels, (F(3,8)= 4.907, p = 0.0320). Dunnett’s multiple comparisons post-hoc 
test shows that SUMOylated 5-HT1AR expression significantly decreased in the group transfected 
with SENP2 as compared to the control, * indicates p<0.05 (D) Graph showing the quantification 
of SUMOylated 5-HT1AR on the blots labelled with anti-5-HT1AR antibody. Data are shown as 
mean ±SEM (n=4). One-way ANOVA shows a significant effect of SENP transfection on 
SUMOylated 5-HT1AR levels (F(3,12) = 4.907, p<0.0001). Dunnett’s multiple comparisons post-
hoc test shows that SUMOylated 5-HT1AR significantly decreased in the group transfected with 
SENP2 as compared to the control. 






















Figure 5. Effect of 8-OH-DPAT treatment on SENP2 expression in the rat 
frontal cortex. 
Ovariectomized female rats were injected with either saline or 8-OH-DPAT (200 µg/kg s.c.) and 
then decapitated after 5 minutes. (A) Western blot showing the effect of 8-OH-DPAT treatment 
on SENP2 expression. (B) Graph showing the quantification of the lower SENP2 bands. (C) Graph 
showing the quantification of the upper SENP2 bands. Unpaired t-test shows significant effect of 
8-OH-DPAT treatment on SENP2 expression. ***p=0.0008 Data are shown as mean ±SEM (n=4).  
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Figure 6. Purification of 5-HT1AR and SUMOylated 5-HT1AR. 
N2a cells were either mock transfected (MT) or transfected with 5-HT1AR and/or 6His-
SUMO1(T95K). (A) Coomassie gel showing the purified 5-HT1AR when immunoprecipitated with 
anti-flag antibody. (B) Western blot showing the expression of purified SUMOylated 5-HT1AR 
using his-tagged pull down upon immunoblotted with anti-5-HT1AR antibody. (C) Western blot 





CHAPTER 4: DISCUSSION 
In this study, we identified that SENP2 is involved in the deSUMOylation of 5-HT1ARs. 
For these experiments, we used mouse neuroblastoma (N2a) cells which express endogenous 5-
HT1AR and SUMO1 machinery [76]. We determined which SENP enzymes are involved in the 
deSUMOylation of 5-HT1ARs using two different approaches. First, we overexpressed different 
flag-tagged SENPs in N2a cells and observed no difference in the amount of SUMOylated 5-
HT1AR in the presence of any SENP. Second, we overexpressed flag-tagged 5-HT1AR and 
SUMO1 along with the SENPs and observed that the amount of SUMOylated 5-HT1AR decreases 
in the presence of SENP2. This difference in the results could be because overexpressing the 
SENPs in N2a cells leads to an increased amount of SUMO1 moieties available for SUMOylation 
since SENPs are also involved in the maturation of the SUMO precursor proteins. The availability 
of SUMO1 moieties might be a rate limiting step in the SUMO pathway and hence we were not 
able to see the deSUMOylating effects of SENPs. Overexpressing SUMO1 in the N2a cells may 
have resulted in observing the deSUMOylating effects of SENP2 on the SUMOylation of 5-
HT1ARs separate from the effects of increasing mature SUMO1. We speculate that the effects we 
observe on the SUMOylated 5-HT1AR due to SENPs is because of overexpression of SUMO1 
alone. The levels of SUMO1 might be too low in N2a cells to see the effects of deSUMOylation 
independent of the effects of SUMO1 maturation. Further studies are needed to confirm this 
interpretation. 
The effects of SENPs on the SUMOylated 5-HT1AR was studied using two different 
antibodies. We observed that the SUMOylated 5-HT1AR band when immunoblotted with the anti-
flag antibody was of a different molecular size from the band labeled with the anti-5-H1AR 




HT1AR antibody labeled the endogenous 5-HT1AR which was observed at 52kD. This could be 
because the N2a cells might be processing the transfected 5-HT1AR differently as compared to 
the endogenous 5-HT1AR.  
 To further confirm the results of our immunoprecipitation and western blot analysis, we 
performed a control experiment to determine the size of SUMOylated 5-HT1AR in different 
species. Membrane fractions of rat and mouse frontal cortex tissue were used in addition to non-
transfected and transfected N2a cell lysates with rat and human 5-HT1AR constructs. First, it was 
confirmed that the anti-5-HT1AR antibody is identifying the SUMOylated 5-HT1AR across 
different species tested. The size of SUMOylated 5-HT1AR was found to be similar in rat, mouse 
and human species i.e. around 52-53 kDa.  
In N2a cells, it was found that SENP2 is involved in the deSUMOylation of 5-HT1ARs. 
Therefore, we examined if the expression of SENP2 decreased in rats treated with 8-OH-DPAT as 
compared to the control, a treatment that leads to the increase in SUMOylation of 5-HT1ARs. We 
observed a significant decrease in a 60kDa isoforms of SENP2 with 8-OH-DPAT treatment but 
not in 50kDa isoform of SENP2.  
There are multiple isoforms of SENP2.  Previous studies observed four different isoforms 
at 60 kDa, 50 kDa, 44 kDa and 40 kDa in HeLa cells [71]. These different isoforms of SENP2 may 
arise due to alternative splicing of the senp2 mRNA. Previous studies have suggested that SENP2 
encodes for three different isoforms generated by alternative splicing, SENP2, SENP2-M and 
SENP-S in human HCT116 cells [72]. Another isopeptidase found in mice, SUMO1 Protease 1 
(SuPr-1) had 87% sequence identical to human SENP2. Based on genomic sequence analysis, 
SuPr-1 appears to be an alternatively spliced product of the senp2 mRNA because it was observed 




quantified two proteins bands one at 50 kDa and one at approximately 60 kDa. We chose the 50 
kDa band because flag-tagged SENP2 is expressed at 50 kDa. We also identified a SENP2 isoform 
at 60 kDa but could not distinguish a 44 or 40 kDa band. With 8-OH-DPAT treatment, no 
difference in SENP2 expression was seen for the 50 kDa, whereas a significant decrease in the 
SENP2 expression was seen in the 60 kDa protein band. Further experiments are needed to confirm 
these findings. Mass spectrometry analysis could also be done to distinguish between the two 
isoforms of SENP2. These mass spectrometry analyses could be used to confirm the amino acid 
sequence of these protein bands. siRNAs could be designed to knockdown specific SENP2 
isoforms, which could be used to determine which SENP2 isoform is directly involved in the 
SUMOylation of 5-HT1ARs. These studies would be important to confirm which SENP2 isoform 
regulates deSUMOylation of 5-HT1ARs.  
We observed that the bands at 60 kDa molecular weight diminished in the membrane 
fraction of 8-OH-DPAT treated in frontal cortex tissue. This could be due to several reasons. First, 
the treatment with 8-OH-DPAT could cause SENP2 to translocate to the cytoplasm from the 
membrane. Second, 5-HT1AR activation further leads to the activation of several downstream 
signaling pathways such phosphoinositide-3-kinase (PI3K)-Akt pathway, extracellular signal-
regulated kinases1 and 2 (ERK1/2) pathway[2]. Activation of these signaling pathways results in 
phosphorylation of different proteins. Activation of these kinases might have resulted in 
phosphorylation of SENP2, which would have resulted in a conformational change in the SENP2 
structure that could not be recognized by the antibody. To identify the 60 kDa isoform of SENP2, 
which may have undergone a conformational change, other anti-SENP2 antibodies could be used. 
To confirm the translocation of SENP2 in the cytoplasm, immunoblotting analysis on the 




could also be performed in order to determine the translocation of SENP2 in the cytoplasm. 
Phosphorylation of SENP2 could be tested using anti-phospho-SENP2 antibodies. Radiolabeling 
assays using radiolabeled 32P-orthophosphate could be performed to determine if SENP2 is indeed 
phosphorylated.  
In the study to determine the effect of 8-OH-DPAT treatment on SENP2 expression, 
animals were treated with 8-OH-DPAT with a single dose of 200 µg/kg and then decapitated after 
5 minutes. It was observed that treatment with 8-OH-DPAT increased SUMOylation of 5-HT1ARs 
[32]. However, in order to determine the optimal dose of 8-OH-DPAT required to increase 
SUMOylation of 5-HT1ARs, dose response studies are needed to be performed. Time course 
studies are also important to study the onset and peak of SUMOylation of 5-HT1AR due to agonist 
treatment.  
Previous studies in our lab have also shown that acute treatment with 8-OH-DPAT increase 
in SUMOylation of 5-HT1ARs which was further increased by a two-day treatment with EB, 
treatments that lead to desensitization of 5-HT1ARs. Previous data also suggests that 
SUMOylation may be playing a role in the desensitization of the 5-HT1ARs [32]. 5-HT1AR 
desensitization is required for anti-depressant action [21]. Hence, understanding the regulation of 
5-HT1ARs by SUMOylation would be useful in the development of better therapeutic targets for 
depression.  
To determine the primary site of SUMOylation, previous studies in our lab have used 
acceptor photobleach FRET to demonstrate that lysine residues 232, 235 and 324 of the amino 
acid sequence of the 5-HT1AR could be possibly involved in SUMOylation. However, further 
studies are needed to confirm these results. We chose to use mass spectrometry to identify the 




unbiased technique to identify post translational modification sites. In order to perform mass 
spectrometry, we needed to purify the SUMOylated 5-HT1AR. For this study cell lysates were 
harvested 32 hours after transfection because the receptor expression was maximal at that 
timepoint. A time-course experiment was performed to determine the optimum time for 5-HT1AR 
expression. We use a hexahistidine (6His)-tagged mutant form of SUMO1 with a single amino 
acid substitution at the C-terminal end of the molecule, where the amino acid preceding the 
diglycine motif has been mutated to lysine (6His-SUMO1(T95K)), which can be recognized by mass 
spectrometry [75]. Proteins modified by 6His-SUMO1(T95K) are purified using nickel affinity 
purification. Further, these samples will be used for tandem MS/MS analysis of the sites that are 
SUMOylated on the 5-HT1AR.  
Recently, many proteins associated with G-proteins are found to be SUMOylated. 
Metabotropic glutamate receptors are the first G-protein coupled receptors that were shown to be 
SUMOylated. However, function of SUMOylation on mGLuRs is not clear, it is believed that 
SUMO might provide an interface for the binding of many interacting proteins [67]. Cannabinoid 
receptor 1 (CB1) is another GPCR that is known to be SUMOylated [68]. It was found that agonist 
treatment decreased SUMOylation of CB1. Another GPCR, M1 muscarinic acetylcholine 
receptors are SUMOylated [69]. Results suggest that SUMOylation plays an important role in 
regulating ligand-binding affinity and signal transduction of M1 muscarinic acetylcholine 
receptors. Besides GPCRs, many regulators of G-protein signaling such as RGSZ1 and RGSZ2 
are also SUMOylated upon the activation of µ-opioid receptors [70]. Studies suggest that 
SUMOylation of RGSZ1 and RGSZ2 mediate desensitization of GPCRs. Since, these studies 
demonstrate that SUMOylation alters GPCR function, it is important to study the role of 




In conclusion, this study identified that SENP2 is involved in the deSUMOylation of 5-
HT1ARs. We also found decreased levels of one of the SENP2 isoforms in the frontal cortex of 
rats with the 8-OH-DPAT treatment. However, further studies are needed to confirm this result 
and the mechanism responsible for decrease in the expression of SENP2 with 8-OH-DPAT 
treatment. Hence, SENP2 can used as a target for the regulation of SUMOylation of 5-HT1ARs 
and could be used to modulate 5-HT1AR function. Mass spectrometry studies will be conducted 
to find the primary site of SUMOylation on the 5-HT1ARs. Determining the site at which 
SUMOylation occurs will help us further understand the 5-HT1AR structure and function. 
Together these studies, further our understanding of the mechanism regulating SUMOylation of 
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